Kinase, in vitro: 

An enzyme-substrate reaction that occurs in non-living experimental conditions such as a test tube. For example, a purified enzyme is reacted with a substrate protein or mixture of proteins or peptides.

Akt1 S259-p
ERK1 S289-p , S296-p , S301-p
KSR T269-p
PAK1 S338-p , S339-p
PAK2 S338-p
PAK3 S338-p
PKACA S43-p , S259-p , S621-p
PKCA S499-p
PKCA S497-p , S619-p
RAF1 S259-p , S338-p , S359-p , S621-p
Src Y340-p , Y341-p
 Putative in vivo kinases: 

An enzyme-substrate reaction that occurs within living cells; includes cultured cells, ex vivo samples, and intact organisms. In the case of kinases, the large number of protein kinases in intact cells makes exact identification of the responsible kinase challenging.

AMPKA1 S259-p , S621-p
ERK1 S289-p , S296-p , S301-p
KSR T269-p
LATS1 S259-p
MEK1 S338-p
PAK1 S338-p
PAK2 S338-p
PAK3 S338-p
PKACA S621-p
PKACA S43-p , S259-p , S621-p
PKACA S43-p
PKCA S43-p , S499-p
PKCA S497-p , S619-p
RAF1 S621-p
Src Y340-p , Y341-p
Src Y341-p
Phosphatases, in vitro:
PPP2CB S259-p
PPP5C S338-p
Putative upstream phosphatases:
PPP2CA S259-p
PPP5C S338-p
Regulatory protein:
14-3-3 zeta S259-p
Akt1 S259-p
ARAF S259-p
CD38 S233-p , S642-p
CDK10 S338-p
DLX3 S338-p
DOCK1 S338-p
ENaC-beta S259-p , S289-p , S338-p
ERas S259-p , S338-p
ERK1 S289-p , S296-p , S301-p
HRas S338-p , T491-p
KRas S338-p
LATS1 S259-p
LATS2 S259-p
Lck S338-p
LYN S259-p , S289-p , S296-p , S301-p
MAD2L1 S259-p
MEK1 S259-p
MLC1 S338-p
MLK3 T491-p , S494-p
MRas S259-p
MST2 S259-p , S338-p
NDRG3 S338-p
osteopontin S259-p , S338-p
PAK1 S338-p
PDE8A S259-p
PHB S338-p
PIN1 S338-p
PKCE S338-p
PLA2G7 S338-p
PPP1R14B S338-p
PPP5C S338-p
RAF1 S259-p , S338-p , T491-p
RHEB S338-p
SHC1 Y340-p , Y341-p
SHOC2 S259-p
Src S338-p
TSLP S296-p
Treatment:
5-aza-CdR S259-p
A-443654 S338-p
Akt-I-1 S259-p
antibody S338-p
arachidonic_acid S259-p
ATP S359-p
AzaC S338-p
BAPTA-AM S338-p
bradykinin S338-p
C8-ceramide T269-p
cAMP_analog S259-p
cell_detachment S338-p
chrysin S301-p
colforsin S43-p , S233-p , S259-p , S338-p , S621-p
compound A S359-p
curcumin S259-p
dasatinib S296-p , S338-p
dronabinol S259-p
EAL S259-p
EDTA S259-p
EGb 761 S338-p , Y341-p
EGF S43-p , S233-p , S259-p , T269-p , S289-p , S296-p , S301-p , S338-p , Y340-p , Y341-p , S471-p , T481-p , T491-p , S494-p , S621-p
estrogen_deprivation S338-p
FGF1 S338-p , Y341-p
fibronectin S338-p
FRAX597 S338-p
gefitinib Y341-p
genistein S338-p
GIP S259-p
GNF2 S338-p
GTP-gammaS S338-p
guanidine S259-p
GW_5074 S338-p
H-89 S259-p , S338-p
IBMX S43-p , S233-p , S259-p , S338-p
IFN-gamma S338-p
IGF-1 S259-p
imatinib S338-p
insulin S338-p
ischemia S29-p , S43-p , S220-p
lactacystin S259-p
low_K(+) S259-p
LY294002 S259-p , S338-p
LY3009120 S338-p
M-CSF S43-p , S259-p , S621-p
manumycin_A S338-p
metastatic potential S621-p
methyl-beta-cyclodextrin S338-p
MG132_withdrawal S621-p
nilotinib S338-p
nocodazole S244-p , S338-p
NSC23766 S338-p
okadaic_acid S29-p , S43-p , S259-p , S289-p , S296-p , S301-p , S621-p , S642-p
PAF S338-p
PD0325901 S338-p
PDGF S29-p , S43-p , S289-p , S296-p , S301-p , S338-p , S621-p , S642-p
PF562271 S338-p
phorbol_ester S43-p , S259-p , S338-p , S497-p , S499-p , S621-p
pictilisib S338-p
PKC412 S259-p , S338-p , Y340-p , Y341-p
proanthocyanidin S338-p
PTX S259-p
rapamycin S338-p
retinoic_acid S259-p , S289-p , S296-p , S301-p , S338-p , Y340-p , Y341-p , S621-p
rigosertib S338-p
rimonabant S259-p
SCF S338-p
SCH772984 S338-p
seliciclib S259-p , S289-p , S296-p , S301-p
selumetinib S338-p , S642-p
serum S259-p , S338-p , T491-p
siRNA R100-me , S289-p , S296-p , S301-p , S338-p , T491-p , S494-p
sorafenib S338-p
sotorasib S338-p
SR_144528 S259-p
SU6656 S338-p
taxol S259-p
thymidine S244-p
TNF T269-p , S338-p
U0126 S29-p , S43-p , S289-p , S296-p , S301-p , S338-p , S471-p , T481-p , S642-p
vanadate S338-p , Y341-p
vemurafenib S642-p
vincristine S259-p
virus infection S259-p , S338-p
wortmannin S259-p , S338-p
Y27632 S259-p
Z-VAD-FMK S259-p